20-F: GSK plc Releases 2024 Annual Report, Highlights Pipeline Progress and Financial Performance

GSK plc's 2024 Annual Report showcases strong financial performance, pipeline advancements, and a commitment to responsible business practices.

Summary

• GSK plc released its 2024 Annual Report, highlighting financial performance and R&D progress.
• Group sales reached £31.4 billion, a 7% increase at CER (3% AER), driven by Specialty Medicines.
• Excluding COVID-19 solutions, sales grew by 8% CER (4% AER).
• The company reported 13 positive Phase III clinical trial readouts.
• GSK is progressing 14 scale innovation opportunities, with five new product approvals expected in 2025.
• A share buyback program of £2 billion over the next 18 months has been announced.
• The full year dividend for 2024 is 61p, with an expected 64p in 2025.
• GSK aims to positively impact the health of 2.5 billion people by the end of 2030.
• The company invested £6.4 billion in R&D in 2024.
• The report details GSK's commitment to operating as a responsible business, focusing on access, global health, environment, inclusion, ethical standards, and product governance.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong financial results and pipeline progress, but acknowledges challenges and risks, resulting in a moderately positive sentiment.

Positives

• Strong sales growth, particularly in Specialty Medicines.
• Significant progress in the R&D pipeline with multiple positive Phase III readouts.
• Commitment to returning value to shareholders through dividends and share buybacks.
• Focus on responsible business practices and sustainability.
• High employee engagement scores.

Negatives

• Vaccine sales were down 4% CER (7% AER) due to external pressures.
• Share price does not currently reflect confidence in growth strategy.

Risks

• Failure to comply with laws and regulations.
• Adverse outcomes from litigation and government investigations.
• Failure to ensure product quality.
• Inaccurate financial reporting.
• Cyber security threats.
• Supply chain disruptions.
• Failure to deliver pipeline.
• Inadequate skills and capability planning.
• Changes in the regulatory environment.
• Geopolitical developments.
• Climate change and environmental risks.

Future Outlook

GSK expects a series of major launches from 2025 onwards, with peak year sales of over £2 billion, and is focused on pipeline opportunities beyond 2031.

Management Comments

• The Board recognises that the value of GSK shares does not currently reflect our confidence in our growth strategy.
• The Board believes that the balance sheet is now strong enough to support a share buyback.
• The companys core focus remains progressing and strengthening the pipeline and R&D performance.

Industry Context

The announcement reflects GSK's strategic shift towards a focused biopharma model, aligning with industry trends in specialty medicines and vaccine development.

Comparison to Industry Standards

• GSK's R&D cycle times are now in the top quartile for the industry.
• GSK is compared to a size-adjusted global biopharma peer group including Amgen, AstraZeneca, Bayer, BMS, CSL, Gilead, Merck KGaA, Moderna, Novartis, Pfizer, Roche, Sanofi, and Takeda.
• The report mentions GSK's leadership position in the Access to Medicine Index, indicating a commitment to global benchmarks for pharmaceutical companies.

Legal Proceedings

• GSK has reached agreements to settle the vast majority of Zantac cases in the US, but litigation continues.
• GSK is involved in intellectual property disputes related to mRNA and RSV vaccines.
• The company is a defendant in product liability cases related to Avandia and Zofran.

Stakeholder Impact

• Patients: Access to new and improved medicines and vaccines.
• Shareholders: Returns through dividends and share buybacks.
• Employees: Opportunities for challenging and interesting work.
• Society: Contributions to global health and economic prosperity.

Next Steps

• Execute pipeline delivery and prepare for the next wave of innovation.
• Implement the £2 billion share buyback program.
• Progress key assets in RI&I and Oncology.
• Continue to review and evolve actions in responsible business areas.

Key Dates